Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of Moderna versus Pfizer-BioNTech COVID-19 vaccine outcomes: A target trial emulation study in the U.S. Veterans Affairs healthcare system

Published:2022-03 Issue: Volume:45 Page:101326
ISSN:2589-5370
Container-title:eClinicalMedicine
language:en
Short-container-title:eClinicalMedicine

Author:

Ioannou George N.^ORCID,Locke Emily R.,Green Pamela K.,Berry Kristin

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

2. An mRNA vaccine against SARS-CoV-2 - preliminary report;Jackson;N Engl J Med,2020

3. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 vaccine;Baden;N Engl J Med,2021

4. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data;Haas;Lancet,2021

5. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting;Dagan;N Engl J Med,2021

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Vaccine‐induced humoral response of BNT162b2 and mRNA-1273 against BA.1, BA.5, and XBB.1.5. (sub)variants 6 months after a homologous booster: is immunogenicity equivalent?;Heliyon;2024-08

2. Re-thinking all-cause COVID-19 hospitalizations as a surrogate measure for severe illness in observational surveillance studies;Scientific Reports;2024-06-24

3. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination;BMC Medicine;2024-03-08

4. SARS-CoV-2-infection- and vaccine-induced antibody responses are long lasting with an initial waning phase followed by a stabilization phase;Immunity;2024-03

5. Making causal inferences from transactional data: A narrative review of opportunities and challenges when implementing the target trial framework;Journal of International Medical Research;2024-03

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3